The United States Department of Agriculture (USDA)/Animal Plant Health Inspection Service (APHIS)/Wildlife Services
(WS), National Rabies Management Program in Concord, NH, intends to award a sole-source contract to Artemis
Technologies a subsidiary of Ceva Sante Animale SA, for the supply of the oral rabies vaccine ONRAB Ultralite baits. WS proposes to purchase up to
7,500,000 oral rabies vaccine wildlife baits during 2021. This procurement is being conducted in accordance with FAR
6.302-1 and 41 U.S.C. 3304(a)(1). USDA, APHIS, WS and state and federal collaborators conducted field trials during 2011-2018 to evaluate the safety
and efficacy of a human adenovirus type 5-rabies glycoprotein recombinant (AdRG1.3) ONRAB rabies vaccine in
raccoons and striped skunks. To date, Raboral V-RG (a vaccinia-rabies glycoprotein recombinant oral rabies vaccine),
the only oral rabies vaccine licensed for use in the United States to control rabies in raccoons and coyotes, has been
the only oral rabies vaccine used operationally in rabies control campaigns. This vaccine has allowed WS and
cooperators to prevent raccoon rabies from spreading appreciably, but achieving elimination of raccoon rabies is
expected to require higher levels of rabies antibody seroconversion in raccoon populations targeted for oral
vaccination at currently used bait densities. In addition, there is a need to orally vaccinate skunks as raccoon rabies
often spills over into the skunk population, a potential source of re-infection in raccoons. ONRAB has been identified
as a candidate for testing, in part, because this oral vaccine demonstrated higher levels of rabies antibody
seroconversion in raccoons than the oral vaccine currently in use in the United States in two cross-border comparison
studies. In addition, it has produced favorable control in raccoons and, in some cases, skunks in Canada. Although the
recombinant ONRAB vaccine has been used extensively in southern Ontario since 2006 and Quebec since 2007 with
good reported success, these field trials represented the first release of this vaccine into the field in the United States.
This is not a request for competitive proposals. No solicitation documents are available and telephone requests will
not be honored. However, if a firm believes it can meet the requirements it must furnish information about its product
to the Contract Specialist listed on this notice by 4 p.m. central on the closing date of this notice. Supporting evidence
must be furnished in sufficient detail to demonstrate the ability to comply with the above requirement. The NAICS
code for this acquisition is 325414 - Biological Product (except Diagnostic) Manufacturing, and the small business size
standard is 500 Employees.
Responses received after the response date or without the required information will not be considered. Capability
statements may be sent via email: Jason.l.wilking@usda.gov.
The United States Department of Agriculture (USDA)/Animal Plant Health Inspection Service (APHIS)/Wildlife Services
(WS), National Rabies Management Program in Concord, NH, intends to award a sole-source contract to Artemis
Technologies Ceva Sante Animale SA, for the supply of the oral rabies vaccine ONRAB Ultralite baits. WS proposes to purchase up to
7,500,000 oral rabies vaccine wildlife baits during 2021. This procurement is being conducted in accordance with FAR
6.302-1 and 41 U.S.C. 3304(a)(1).
USDA, APHIS, WS and state and federal collaborators conducted field trials during 2011-2018 to evaluate the safety
and efficacy of a human adenovirus type 5-rabies glycoprotein recombinant (AdRG1.3) ONRAB rabies vaccine in
raccoons and striped skunks. To date, Raboral V-RG (a vaccinia-rabies glycoprotein recombinant oral rabies vaccine),
the only oral rabies vaccine licensed for use in the United States to control rabies in raccoons and coyotes, has been
the only oral rabies vaccine used operationally in rabies control campaigns. This vaccine has allowed WS and
cooperators to prevent raccoon rabies from spreading appreciably, but achieving elimination of raccoon rabies is
expected to require higher levels of rabies antibody seroconversion in raccoon populations targeted for oral
vaccination at currently used bait densities. In addition, there is a need to orally vaccinate skunks as raccoon rabies
often spills over into the skunk population, a potential source of re-infection in raccoons. ONRAB has been identified
as a candidate for testing, in part, because this oral vaccine demonstrated higher levels of rabies antibody
seroconversion in raccoons than the oral vaccine currently in use in the United States in two cross-border comparison
studies. In addition, it has produced favorable control in raccoons and, in some cases, skunks in Canada. Although the
recombinant ONRAB vaccine has been used extensively in southern Ontario since 2006 and Quebec since 2007 with
good reported success, these field trials represented the first release of this vaccine into the field in the United States.
This is not a request for competitive proposals. No solicitation documents are available and telephone requests will
not be honored. However, if a firm believes it can meet the requirements it must furnish information about its product
to the Contract Specialist listed on this notice by 1:30 p.m. central on the closing date of this notice. Supporting evidence
must be furnished in sufficient detail to demonstrate the ability to comply with the above requirement. The NAICS
code for this acquisition is 325414 - Biological Product (except Diagnostic) Manufacturing, and the small business size standard is 500 Employees. Responses received after the response date or without the required information will not be considered. Capability statements may be sent via email: Jason.l.wilking@usda.gov.
